AFFIRM Advisory Board Member

EMRA is looking for a resident member of the American Foundation for Firearm Injury Reduction in Medicine (AFFIRM) advisory board. This board is established to provide diverse medical stakeholder expertise and perspective, and to inform AFFIRM’s Board of Directors, Officers, and Research Council on priorities and strategies relevant to AFFIRM’s mission of ending the epidemic of gun violence in America. The membership of the board is comprised of representatives from stakeholder organizations (such as EMRA). Members of the board are appointed for 2 years.


AFFIRM is a non-partisan, non-advocacy based 501c3 comprised of healthcare leaders and researchers who seek to end the epidemic of gun violence through research, innovation and evidence-based practice. 

Application Deadline

Janaury 31


EMRA Resident Members


2 years starting in April of odd numbered year (note, this will be as soon as selected for this year)



The EMRA Representative to the advisory board is responsible for representing all emergency medicine residents and EMRA in discussions about how AFFIRM should perform research and fund research into gun violence and gun mortality reduction. This individual is expected to be knowledge of EMRA’s policies on the issue, and be comfortable representing those at the advisory meetings. This individual is also responsible for periodic reports to the EMRA Board of Directors, and other stakeholders as required. Please note that this is NOT an advocacy-based position. AFFIRM’s mission is based on the idea that firearm injury prevention research is inherently non-partisan and non-controversial. AFFIRM leadership includes gun owners and non-gun owners; but we all agree on the importance of research funding, and the importance of applying science to this injury epidemic.

Advisory meetings will happen remotely, so there is no travel expected for this position.

Specific duties of the members may also include:

  1. Being knowledgeable about relevant research, current events, best practices, and violence prevention efforts
  2. Provide insight into the unique perspectives and needs of each stakeholder group relevant to the risk or consequences of firearm injury or death
  3. Identify and prioritize gaps in knowledge, communication and care relevant to firearm risk or injury/death
  4. Assess opportunities for improved health outcomes
  5. Propose realistic and feasible solutions to identified deficiencies
  6. Make recommendations about strategies to communicate the public health approach to gun violence prevention
  7. Identify and manage policy implications of firearm injury prevention research results
  8. Assist with marketing, promotion and fundraising where feasible and appropriate
  9. Assist with identification and recruitment of new candidates to the AFFIRM Advisory Board, Research Council and Board of Directors


AFFIRM Advisory Board Member Application

In order to apply, please provide EMRA with:

  1. A letter of support from your program director. This letter must include an attestation that he or she will ensure that the resident will have sufficient time to participate in activities of the advisory board.
  2. Your CV
  3. A personal statement (250 word max) about your qualifications and goals for the position.

Please submit PDF formatted files for your Letter of Support and CV.


Related Content

Dec 16, 2019

Making Sense of Graduate Medical Education Funding

The crux of this article: Actively advocating for GME funding is the responsibility of all physicians, regardless of where they are in training, so the future of health care and safety of patients is protected. Read on ...

Dec 16, 2019

Hotspotting: Rethinking Health Care Delivery

What is hotspotting, and why should you care? It's a critical concept in the ED arena and may help care for the most vulnerable of patients.

Oct 09, 2019

Critical Care Alert: Epinephrine for Out-of-Hospital Cardiac Arrest

This review article was trying to take another look at the impact of epinephrine, especially its impact on meaningful neurologic survival, to see if the debates launched by the PARAMEDIC-2 trial were justified.